Valuation: Shanghai Rightongene Biotechnology Co., Ltd.

Market Cap 1.22B 179M 157M 145M 134M 254M 17.02B 259M 1.73B 674M 8.4B 673M 659M 29.03B P/E 2024
-65.9x
P/E 2025 -29x
Enterprise Value 996M 147M 128M 118M 110M 208M 13.91B 211M 1.42B 551M 6.87B 550M 538M 23.73B EV / Sales 2024
3.33x
EV / Sales 2025 6.95x
Free-Float
62.67%
Yield 2024 *
-
Yield 2025 -
04-27 Shanghai Rightongene Biotechnology Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2026 CI
02-27 Shanghai Rightongene Biotechnology Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2025 CI
25-10-16 Shanghai Rightongene Biotechnology Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2025 CI
25-09-08 Shanghai Rightongene Biotechnology's boards elects chairman RE
25-08-28 Shanghai Rightongene Biotechnology Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2025 CI
25-04-24 Shanghai Rightongene Biotechnology Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2025 CI
25-02-27 Shanghai Rightongene Biotechnology Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2024 CI
25-02-25 Shanghai Rightongene Biotechnology Receives 1.8 Million Yuan in Government Subsidies MT
25-02-19 Tranche Update on Shanghai Rightongene Biotechnology Co., Ltd.'s Equity Buyback Plan announced on February 29, 2024. CI
25-02-17 Shanghai Rightongene Biotechnology Co., Ltd.'s Equity Buyback announced on February 29, 2024, has closed with 669,621 shares, representing 1.2% for CNY 17.02 million. CI
25-01-02 Tranche Update on Shanghai Rightongene Biotechnology Co., Ltd.'s Equity Buyback Plan announced on February 29, 2024. CI
24-10-29 Shanghai Rightongene Biotechnology Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2024 CI
24-10-28 Rightongene Biotechnology's Chairman, Vice General Managers Arrested for Fraud Suspicion; Shares Down 4% MT
1 day-3.29%
1 week+8.61%
Current month+6.87%
1 month-8.50%
3 months-19.21%
6 months-23.97%
Current year-16.20%
1 week 20.21
Extreme 20.21
23.34
1 month 19.32
Extreme 19.32
24.5
Current year 19.32
Extreme 19.32
33.27
1 year 19.32
Extreme 19.32
36
3 years 12.38
Extreme 12.38
43.05
5 years 12.38
Extreme 12.38
103.01
10 years 12.38
Extreme 12.38
133.67
Manager TitleAgeSince
Chief Executive Officer 69 2024-07-21
Director of Finance/CFO 34 2025-01-26
Investor Relations Contact - -
Director TitleAgeSince
Chairman 69 2024-07-21
Director/Board Member 41 2019-05-12
Director/Board Member 53 2023-08-23
Change 5-day change 1-year change 3-year change Capi.($)
-3.29%+8.61%-17.77%-44.00% 179M
-3.49%+8.59%+228.87%+338.07% 21.6B
-2.62%-2.07%-42.31%-24.16% 9.51B
+0.57%-6.79%+30.58%+25.50% 6.73B
-5.42%-1.33%+217.37%-29.81% 4.8B
-1.91%-1.96%-34.15% - 4.94B
-3.71%-8.26%-27.41%-35.76% 4.56B
-0.03%-1.15%-24.98%-26.80% 4.06B
-5.61%-10.59%+63.61%+72.24% 3.69B
-2.02%+2.01%-18.84%-40.86% 2.56B
Average -2.39%-1.74%+37.50%+26.05% 6.26B
Weighted average by Cap. -2.53%+0.92%+89.08%+121.04%

Financials

2024 2025
Net sales 242M 35.66M 31.21M 28.76M 26.66M 50.6M 3.38B 51.42M 345M 134M 1.67B 134M 131M 5.77B 177M 26.09M 22.83M 21.04M 19.5M 37.02M 2.48B 37.61M 252M 98.11M 1.22B 97.94M 95.82M 4.22B
Net income -15.76M -2.32M -2.03M -1.87M -1.73M -3.29M -220M -3.35M -22.44M -8.72M -109M -8.71M -8.52M -376M -50.38M -7.41M -6.49M -5.98M -5.54M -10.52M -704M -10.69M -71.7M -27.88M -347M -27.83M -27.23M -1.2B
Net Debt -210M -30.95M -27.08M -24.96M -23.14M -43.92M -2.94B -44.63M -299M -116M -1.45B -116M -114M -5.01B -223M -32.75M -28.66M -26.41M -24.48M -46.47M -3.11B -47.22M -317M -123M -1.53B -123M -120M -5.3B
Logo Shanghai Rightongene Biotechnology Co., Ltd.
Shanghai Rightongene Biotechnology Co Ltd is a China-based company mainly engaged in the research and development, production, sales, scientific research, and testing services of in vitro diagnostic products. The Company mainly provides self-branded molecular diagnostic reagents, scientific research services, testing services, and molecular testing equipment. The Company's main products are molecular diagnostic kits for leukemia, lymphoma, solid tumors, and infectious disease related genes. The Company's main services include providing third-party medical testing services for various medical institutions, pharmaceutical companies, individual patients, and others, as well as providing genetic testing research services for research hospitals, pharmaceutical companies, scientific research institutions, third-party testing institutions and other enterprises and institutions.
Employees
336
Date Price Change Volume
26-07-07 CN¥22.08 -3.29% 1,015,753
26-07-06 CN¥22.83 +1.65% 1,249,972
26-07-03 CN¥22.46 +3.26% 1,556,709
26-07-02 CN¥21.75 +2.30% 1,748,711
26-07-01 CN¥21.26 +2.90% 1,056,951

Annual profits - Rate of surprise

  1. Stock Market
  2. Stocks
  3. 688217 Stock